Related Experiment Video
Updated: Aug 5, 2026
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical
Samuel Obiosa Onyekweli1, Gloria Osayamen Omoruyi1, Christopher Oloruntoba Akintayo1
1Department of Internal Medicine, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria.
Abstract:
Chimeric antigen receptor T-cell (CAR-T) therapy has produced remarkable therapeutic results in blood cancers, while its application to solid malignancies remains limited by a pooled objective response rate of approximately 9%. This gap stems from core biological obstacles: heterogeneous antigen expression, physical inaccessibility within dense stromal architectures, and immunosuppressive microenvironments that drive T-cell exhaustion through epigenetically fixed transcriptional programs. The period spanning 2024-2025 represents a pivotal turning point. GD2-targeting CAR-T cells delivered intracerebroventricularly achieved durable complete responses (including one sustained beyond 30 months) in H3K27M-mutated diffuse midline gliomas. CLDN18.2-targeting satricabtagene autoleucel demonstrated randomized superiority over physician's choice in advanced gastric cancer (progression-free survival HR 0.37). GPC3-targeting CAR-T cells armored with a dominant-negative TGF-β receptor achieved objective response rates of 50-57% in hepatocellular carcinoma, representing a three- to four-fold improvement over unarmored predecessors. These breakthroughs reflect a paradigm shift from potency-driven engineering toward resilience-based design: metabolic armoring via autocrine IL-10 and IL-15, epigenetic protection through DNMT3A disruption and c-Jun overexpression, logic-gated targeting via synNotch circuits, and microenvironmental shielding through dominant-negative receptors. Beyond the local microenvironment, emerging recognition of systemic neuroendocrine-immune dysregulation further informs CAR-T persistence and fitness considerations. This review synthesizes the mechanistic insights, engineering strategies, clinical evidence, and emerging platforms, including in vivo lentiviral CAR-T generation, that define the current landscape, and proposes a tiered framework for next-generation solid tumor CAR-T development, while explicitly acknowledging the limitations and unknowns that persist.
Insights
Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for solid tumors. Recent breakthroughs in engineering CAR-T cells for resilience and targeting specific antigens are improving response rates in challenging cancers.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized blood cancer treatment but faces significant challenges in solid tumors, with response rates around 9%.
- Key obstacles include tumor antigen heterogeneity, physical barriers within dense tumor stroma, and immunosuppressive microenvironments that induce T-cell exhaustion via epigenetic reprogramming.
- Recent advancements in CAR-T cell engineering and delivery strategies are beginning to overcome these limitations.
Purpose of the Study:
- To review recent breakthroughs and emerging strategies in CAR-T therapy for solid tumors.
- To synthesize mechanistic insights, engineering approaches, and clinical evidence defining the current landscape of solid tumor CAR-T development.
- To propose a framework for next-generation CAR-T therapies targeting solid malignancies.
Main Methods:
- Review of recent clinical trials and preclinical research in CAR-T therapy for solid tumors.
- Analysis of novel engineering strategies focused on enhancing T-cell resilience and overcoming the tumor microenvironment.
- Synthesis of data on emerging platforms, including in vivo CAR-T generation and advanced targeting circuits.
Main Results:
- Intracerebroventricular GD2-targeting CAR-T cells achieved durable complete responses in diffuse midline gliomas.
- Satricabtagene autoleucel (CLDN18.2-targeting) demonstrated superiority in advanced gastric cancer.
- GPC3-targeting CAR-T cells armored with a dominant-negative TGF-β receptor showed significantly improved response rates (50-57%) in hepatocellular carcinoma.
Conclusions:
- Engineering CAR-T cells for resilience, through metabolic, epigenetic, and microenvironmental shielding strategies, is crucial for solid tumor efficacy.
- Emerging strategies like logic-gated targeting and in vivo generation hold significant potential for future CAR-T development.
- Further research is needed to address persistent limitations and optimize CAR-T therapy for broad application in solid tumors.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment